Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications

Abstract

Dose kinetics and side effects of viloxazine (VLX) in 16 healthy volunteers (range age 25–90 years) were studied after single oral administration of 200 mg of VLX. Significant differences in peak plasma values (Pt _1/2 (PPPPt _1/2 and Cl/F, due to the high interindividual variability in pharmacokinetic profiles. Total reported and observed side effects scores were higher overall in subjects under 50 years than over 60 years and were inversely correlated to AUC (PP<0.05). Our data support the importance of single dose kinetic studies, particularly for new antidepressants, in relation to age, both to emphasize differences in pharmacokinetic profiles and to predict side effects during chronic treatment.